Blue Foundry Bancorp 

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors. Its preclinical programs include FPA157, an anti-CCR8 antibody that is engineered to eliminate CCR8-expressing CD4+ regulatory T cells within solid tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, and BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California. As of April 16, 2021, Five Prime Therapeutics, Inc. operates as a subsidiary of Amgen Inc.